CDKL2
protein-codingcyclin dependent kinase like 2, the group of Cyclin dependent kinases
Gene summary
This gene product is a member of a large family of CDC2-related serine/threonine protein kinases. It accumulates primarily in the cytoplasm, with lower levels in the nucleus. [provided by RefSeq, Jul 2008]
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~54.2 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
No GenCC data available for this gene.
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to CDKL2 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_001330724.2. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 0 | |||||
| missense | 1 | 73 | 5 | 79 | ||
| nonsense | 1 | 1 | ||||
| start loss | 0 | |||||
| frameshift | 0 | |||||
| splice donor/acceptor (+/-2bp) | 2 | 2 | ||||
| Total | 0 | 1 | 76 | 5 | 0 | 82 |
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_001317653.1 | 12 | MANE Select | |
| Ensembl | ENSP00000306340.4 | 12 | MANE Select | |
| RefSeq | NP_003939.1 | 10 | Standard | |
| Ensembl | ENSP00000412365.2 | 10 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- EMT transition in Colorectal Cancer
Biological Process
- protein phosphorylation
- signal transduction
- sex differentiation
- regulation of cell cycle
Molecular Function
- protein kinase activity
- cyclin-dependent protein serine/threonine kinase activity
- ATP binding
Cellular Component
- nucleus
- cytoplasm
- centrosome
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000429927
- Coding exons
- 10
- Length
- 52686
- Individuals with no LoFs
- 123331
- Homozygous LoFs
- 18
- Heterozygous LoFs
- 2398
- Defined
- 125747
- p
- 0.00965
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | -0.246 | 263 | 252 | 1.04 | 0.0000118 | 3271 |
| Missense (PolyPhen) | 70 | 73.715 | 0.9496 | 966 | ||
| Synonymous | -0.0988 | 91 | 89.8 | 1.01 | 0.00000457 | 894 |
| Loss of Function | -0.113 | 25 | 24.4 | 1.02 | 0.00000138 | 319 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.0023 | 0.0022 | notable |
| Latino/Admixed American | 0.0057 | 0.0048 | notable |
| Ashkenazi Jewish | 0.0043 | 0.0040 | notable |
| East Asian | 0.0044 | 0.0041 | notable |
| Finnish | 0.022 | 0.022 | notable |
| European (Non-Finnish) | 0.014 | 0.013 | notable |
| South Asian | 0.0016 | 0.0014 | notable |
| Other | 0.013 | 0.012 | notable |
dbNSFP Gene Annotations
Source:
Recessive Scores
- pRec
- 0.178
Intolerance Scores
- LoFtool
- 0.714
- RVIS EVS
- -0.07
- RVIS percentile EVS
- 48.54
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Essential (gene trap)
- N
- Indispensability pred.
- N
- Indispensability score
- 0.0385
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |